INTRODUCTION {#sec1-1}
============

Bicuspid aortic valve (BAV) disease is considered the most common congenital heart disease and the most common cause of aortic valve stenosis (AS) in young adults. Up to 50% of patients with BAV require aortic valve replacement in their lifetime.\[[@ref1]\] This is because of the flow hemodynamics of the aortic valve which expedites the degeneration of the valve leaflets prematurely. The current guidelines recommend routine echocardiogram follow-up of patients with BAV to evaluate the valve hemodynamics, severity of the valve stenosis, and the left ventricular function.

Although transcatheter aortic valve replacement (TAVR) has been used routinely in high- and extreme-risk AS patients, BAV patients with AS were excluded from many pivotal trials that led to approval of TAVR in the United States.\[[@ref2][@ref3][@ref4][@ref5]\] This is mainly due to the concomitant aortopathy, which requires aortic root repair with a potential increased risk of aortic dissection and numerous technical challenges related to bicuspid anatomy.\[[@ref6][@ref7][@ref8]\] Therefore, the treatment of choice for symptomatic bicuspid stenosis has been surgical aortic valve replacement (SAVR).\[[@ref9]\]

With the advances in device technology, and with the accumulated experience, there has been an increased off-label use of TAVR for bicuspid stenosis in the absence of aortopathy.\[[@ref10]\] Majority of the evidence for safety and feasibility of TAVR in patients with BAV is based on registry data and single-center experiences. There are limited data regarding the use and outcome of TAVR in BAV stenosis in the United States. We sought, therefore, to assess the trend of TAVR use in patients with BAV stenosis over the past few years and examine the subsequent in-hospital and procedural outcomes.

MATERIALS AND METHODS {#sec1-2}
=====================

Data were obtained from the Agency for Healthcare and Research, and Quality Healthcare Cost and Utilization Project National Inpatient Sample (NIS) files from January 1, 2011 through December 31, 2014. The NIS is the largest, publicly available, all-payer administrative claims database in the United States. It contains de-identified patient and clinical data from approximately 1,000 nonfederal hospitals in 45 states, including approximately 5--8 million discharges annually.\[[@ref11]\]

We identified patients with BAV with International Classification of Diseases-Ninth Revision-CM (ICD-9) code 746.4. Patients undergoing TAVR were identified using ICD-9 codes 35.05 and 35.06. We also obtained the data of those who underwent SAVR were identified using ICD-9 codes 35.21 and 35.22 during the same period. To maintain a homogenous study population and to limit confounding, those with concomitant aortic valve disease were excluded from the analysis in addition to patients undergoing concomitant procedures. Procedure-related complications were identified using appropriate ICD-9-CM codes in any secondary diagnosis field. All measures for comorbidities, except coronary artery disease and anticoagulation history, were created from definitions in the Elixhauser Co-morbidity Index, which assigns variables that identify comorbidities in hospital discharge records using the diagnosis coding of ICD-9-CM.\[[@ref12]\]

Major complications were recorded using established Valve Academic Research Consortium (VARC II) definitions for death, major bleeding, myocardial infarction, stroke, vascular complications, valve-related dysfunction, and acute kidney injury.\[[@ref13]\] Hospital length of stay (LOS) was defined as the number of days from the date of the procedure to the date of being discharged home or to a rehabilitation facility.

A value of *P* \< 0.05 was considered statistically significant. We used the Statistical Package for the Social Sciences software version 25.0 software (IBM, Armonk, NY) for all statistical analyses.

To account for potential confounding factors and reduce the effect of selection bias, a propensity-score-matching model was developed to derive two matched groups for comparative outcomes analysis. Propensity score was calculated using multivariable logistic regression models derived from hospital level, clinical, and demographic covariates, including the Elixhauser comorbidities. For calculation of the propensity score, the dependent variable was the TAVR vs. SAVR procedure use. We performed matching on the propensity score implementing a greedy algorithm to construct a balanced match of TAVR cases to SAVR cases in a 1:1 ratio using a caliper of 0.1. As we used publicly accessible, de-identified administrative level aggregate data, rather than patient-specific data, approval from the institutional review board was not required to conduct the study.

RESULTS {#sec1-3}
=======

A total of 37,052 patients were found to have BAV stenosis. Among them, 36,629 patients (98.8%) underwent SAVR, whereas 423 patients (1.14%) underwent TAVR between January 1, 2011, and December 31, 2014. Compared with SAVR counterparts, patients with BAV who underwent TAVR were older (65.9 years ± 15.1 vs. 56.7 years ± 14.7), had more Caucasian women (34.3% vs. 26.3%), but had more co-morbidities, particularly CAD, hyperlipidemia, prior stroke, and complicated diabetes \[[Table 1](#T1){ref-type="table"}\]. The vast majority of TAVR procedures were performed in large teaching hospitals. Baseline differences existed between the groups after the propensity-adjusted analysis \[[Table 2](#T2){ref-type="table"}\].

###### 

Baseline characteristics and comorbidities in bicuspid aortic valve stenosis patients who underwent either surgical or transcatheter aortic valve replacement

  Variable                               SAVR (*N* = 36,629)   TAVR (*N* = 423)   *P* value
  -------------------------------------- --------------------- ------------------ -----------
  Age                                    56.7 ± 14.7           65.9 ± 15.1        \<0.001
  Sex                                                                             
   Female                                26.3                  34.3               \<0.001
  Race                                                                            0.027
   White                                 85.3                  89.2               
   Black                                 2.1                   2.4                
   Hispanic                              5.9                   4.8                
   Asian or Pacific Islander             1.4                   2.4                
   Native American                       0.4                   0.0                
   Other                                 3.6                   1.2                
  Elective hospitalization               78.8                  79.6               0.112
  Primary expected payer                                       \<0.001            
   Medicare                              31.1                  31.4               
   Medicaid                              6.8                   6.8                
   Private insurance                     55.6                  55.4               
   Self-pay                              2.9                   2.9                
   No charge                             0.4                   0.4                
   Other                                 3.2                   3.1                
  Median household income (percentile)                         \<0.001            
   0--25                                 19.0                  19.1               
   26--50                                24.6                  24.5               
   51--75                                27.3                  27.3               
   76--100                               29.1                  29.1               
  Bed size                                                     \<0.001            
   Small                                 7.4                   2.4                
   Medium                                19.0                  14.2               
   Large                                 73.6                  83.5               
  Location/teaching status                                     0.001              
   Rural                                 1.7                   0.0                
   Urban nonteaching                     18.7                  10.4               
   Urban teaching                        79.6                  89.6               
  Hospital region                                              0.114              
   Northeast                             21.8                  22.2               
   Midwest                               26.2                  23.1               
   South                                 31.5                  33.1               
   West                                  20.5                  23.4               
  Carotid artery disease                 2.4                   3.5                0.153
  Coronary artery disease                32.6                  42.3               \<0.001
  Smoking                                12.9                  7.1                \<0.001
  Hyperlipidemia                         48.9                  55.5               0.008
  Prior stroke                           4.9                   8.1                0.003
  Atrial fibrillation                    33.5                  35.3               0.469
  Alcohol abuse                          3.6                   3.5                1.000
  Deficiency anemia                      13                    15.4               0.165
  RA/collagen vascular disease           1.9                   5.9                \<0.001
  Chronic blood loss anemia              0.9                   2.4                0.008
  Congestive heart failure               0.9                   15.4               \<0.001
  Chronic lung disease                   16.7                  16.7               \<0.001
  Coagulopathy                           28.1                  23.6               0.045
  Depression                             7.9                   10.6               0.043
  Obesity                                17.5                  9.5                \<0.001
  Weight loss                            2.8                   8.3                \<0.001
  Uncomplicated DM                       14.9                  17.7               0.112
  Complicated DM                         2.4                   7.1                \<0.001
  Drug abuse                             0.0                   2.1                \<0.001
  Hypertension                           61.3                  70.7               \<0.001
  Hypothyroidism                         8.5                   8.5                0.111
  Liver disease                          1.8                   1.8                \<0.001
  Lymphoma                               0.4                   0.0                0.417
  Fluid and Electrolyte disorders        33.9                  33.8               0.003
  Other neurological disorders           3.9                   3.9                0.377
  Paralysis                              0.9                   1.0                0.008
  PVD                                    30.4                  30.3               \<0.001
  Renal failure                          6.6                   6.8                \<0.001
  Pulmonary circulation disorders        0.4                   0.4                \<0.001
  Psychosis                              2.1                   2.1                0.056

PCI = percutaneous coronary intervention;

CABG = coronary artery bypass graft; RA = Rheumatoid arthritis; DM = diabetes; PVD = peripheral vascular disease.

###### 

Baseline characteristics and comorbidities in a matched cohort of bicuspid aortic valve stenosis patients who underwent either surgical or transcatheter aortic valve replacement

  Variable                               SAVR (*N* = 68)   TAVR (*N* = 68)   *P* value
  -------------------------------------- ----------------- ----------------- -----------
  Age                                    64.6 ± 12.4       65.0 ± 14.8       0.871
  Sex                                                                        
   Female                                27.9              32.4              0.709
  Race                                                                       0.126
   White                                 85.3              88.2              
   Black                                 10.3              1.2               
   Hispanic                              2.9               5.9               
   Asian or Pacific Islander             0.0               2.9               
   Other                                 1.5               1.5               
  Elective hospitalization               80.9              77.9              0.832
  Primary expected payer                                                     0.676
   Medicare                              45.6              52.9              
   Medicaid                              5.9               5.9               
   Private insurance                     48.5              41.2              
  Median household income (percentile)                                       0.618
   0--25                                 23.5              29.4              
   26--50                                25.0              16.2              
   51--75                                25.0              26.5              
   76--100                               26.5              27.9              
  Bed size                                                                   0.603
   Small                                 5.9               2.9               
   Medium                                16.2              13.2              
   Large                                 77.9              83.8              
  Location/teaching status                                                   0.325
   Urban nonteaching                     4.4               7.4               
   Urban teaching                        95.6              92.6              
  Hospital region                                                            0.158
   Northeast                             235               22.1              
   Midwest                               27.9              19.1              
   South                                 36.8              32.4              
   West                                  11.8              26.5              
  Carotid artery disease                 44.1              44.1              1.000
  Coronary artery disease                4.4               4.4               1.000
  Smoking                                11.8              5.9               0.365
  Hyperlipidemia                         42.6              57.4              0.122
  Prior stroke                           10.3              10.3              1.000
  Atrial fibrillation                    33.8              36.8              0.858
  Alcohol abuse                          1.5               4.4               0.619
  Deficiency anemia                      13.2              14.7              1.000
  RA/collagen vascular disease           2.9               4.4               1.000
  Chronic blood loss anemia              1.5               1.5               1.000
  Congestive heart failure               4.4               0.0               0.244
  Chronic lung disease                   23.5              25.0              1.000
  Coagulopathy                           29.4              23.5              0.560
  Depression                             13.2              11.8              1.000
  Obesity                                10.3              13.2              0.449
  Weight loss                            5.9               5.9               1.000
  Uncomplicated DM                       19.1              17.6              1.000
  Complicated DM                         4.4               5.9               1.000
  Drug abuse                             2.9               0.0               0.496
  Hypertension                           36.8              72.1              0.849
  Hypothyroidism                         11.8              11.8              1.000
  Liver disease                          5.9               2.9               0.680
  Fluid and electrolyte disorders        30.9              25.0              0.567
  Other neurological disorders           4.4               5.9               1.000
  Paralysis                              1.5               2.9               1.000
  PVD                                    19.1              23.5              0.676
  Renal failure                          20.6              19.1              1.000
  Pulmonary circulation disorders        1.5               0.0               1.000
  Psychosis                              1.5               4.4               0.619

PCI = percutaneous coronary intervention,

CABG = coronary artery bypass graft, RA = rheumatoid arthritis, DM = diabetes, PVD = peripheral vascular disease

The number of patients with a BAV stenosis who underwent TAVR significantly increased from 0.39% in 2011 to 4.16% in 2014 (*P* \< 0.001), which represents a 3.77% overall growth in procedure rate \[[Figure 1](#F1){ref-type="fig"}\]. The median LOS was 10.2 days and decreased significantly throughout the above period (mean \[SD\] 12.2 \[8.2\] days to 7.1 \[5.9\] days, *P* \< 0.001) \[[Figure 2](#F2){ref-type="fig"}\].

![Trend of transcatheter aortic valve replacement (TAVR) in patients with bicuspid aortic valve (BAV) stenosis](AJM-10-22-g001){#F1}

![Trends in length of hospital stay](AJM-10-22-g002){#F2}

No statistically significant difference in the need for permanent pacemaker placement or the incidence postoperative aortic rupture was observed. On the contrary, the overall vascular complications, the need for blood transfusion, and the requirement for emergent open cardiac surgery have declined over the same period \[[Figure 3](#F3){ref-type="fig"}\].

![In-hospital outcomes following TAVR in patient with BAV stenosis](AJM-10-22-g003){#F3}

After propensity matching of 68 patients \[[Table 3](#T3){ref-type="table"} and [Figure 4](#F4){ref-type="fig"}\], there was no statistically significant difference between SAVR and TAVR groups in the in-hospital mortality (0% vs. 5.9%; adjusted *P* = 0.119), vascular and cardiac complications, perioperative stroke, acute kidney injury, and permanent pacemaker placement between the two groups. On the contrary, respiratory complications were significantly lower in patients who underwent TAVR (11.8% vs. 29.4%, adjusted *P* = 0.011).

###### 

In-hospital outcomes of a matched cohort of bicuspid aortic valve stenosis patients who underwent either surgical or transcatheter aortic valve replacement

  Outcome                                                                                                                                             SAVR (*N* = 68)   TAVR (*N* = 68)   *P* value
  --------------------------------------------------------------------------------------------------------------------------------------------------- ----------------- ----------------- -----------
  In-hospital mortality                                                                                                                               0%                5.9%              0.11
  Need for blood transfusion                                                                                                                          13.2%             7.4%              0.39
  Vascular complication                                                                                                                               1.5%              2.9%              1.00
   Injury to blood vessels, accidental puncture, injury to retro-peritoneum, other vascular complications, vascular complications requiring surgery                                       
  Cardiac complications                                                                                                                               14.7%             8.8%              0.42
  Permanent pacemaker insertion                                                                                                                       10.3%             10.3%             1.00
  Perioperative stroke                                                                                                                                0%                1.5%              1.00
  Emergent open cardiac surgery                                                                                                                       100%              26.5%             \<0.001
  AKI                                                                                                                                                 17.6%             14.7%             0.81
  Discharge to facility                                                                                                                               22.1%             13.2%             0.26
   Including short term in other hospitals, skilled nursing facility, intermediate care facility, and another type of facility                                                            
  Respiratory complications                                                                                                                           29.4%             11.8%             0.01
   Post-operative acute pneumothorax, postoperative pulmonary edema, pulmonary collapse, prolonged mechanical ventilation \>96h, tracheostomy                                             

SAVR = surgical aortic valve replacement, TAVR = transcatheter aortic valve replacement, AKI = acute kidney injury

![In-hospital outcomes of a matched cohort of bicuspid aortic valve stenosis patients who underwent either surgical or transcatheter aortic valve replacement](AJM-10-22-g004){#F4}

DISCUSSION {#sec1-4}
==========

The findings of our study suggest an increase in the adoption of TAVR for BAV stenosis patients in the United States with overall comparable in-hospital outcomes in those who underwent TAVR and their counterpart in the SAVR cohort.

Patients with BAV were excluded from major early TAVR trials\[[@ref2][@ref3][@ref4][@ref5]\] because of several concerns that BAV anatomy might lead to a less than optimal prosthetic valve positioning and expansion leading to significant paravalvular regurgitation or annulus rupture. In addition, the presence of concomitant aortopathy with a potential increased risk of aortic dissection or rupture as well as a questionable long-term durability of transcatheter valves in younger patients with longer life expectancy. Nevertheless, the accumulated experience and advances in device technology have led to the increased off-label use of TAVR for bicuspid AS.\[[@ref10]\] Early report by Wijesinghe *et al.*\[[@ref14]\] showed the feasibility of TAVR in 11 patients with severe BAV stenosis. Edwards SAPIEN valves (Edwards Lifesciences, Irvine, CA) were implanted successfully in all patients with significant hemodynamic improvement, but two patients (18.2%) had a moderate paravalvular leak. Although Mylotte *et al.*\[[@ref15]\] showed that TAVR using the first-generation balloon-expandable valves (SAPIEN) or self-expanding valves (Medtronic CoreValve, Medtronic, Dublin, Ireland) were feasible with encouraging short- and intermediate-term clinical outcomes reporting a device success rate of 89.9% and a one-year mortality rate of 17.5% however, a high incidence of post-implantation aortic regurgitation was observed in about 28% of the cases.

More recently, Perlman *et al.*\[[@ref16]\] showed that TAVR in BAV stenosis using a new-generation device was feasible and effective with favorable valve performance and no cases of moderate or severe aortic regurgitation. Yoon *et al.*\[[@ref17]\] provided a head-to-head comparison between the early- and new-generation devices in BAV stenosis patients undergoing TAVR and showed an all-cause mortality rate of 4.3% at 30 days and 14.4% at 1 year. The outcome was comparable to TAVR outcomes in patients with tricuspid AS. Interestingly, there were no cases of moderate or severe paravalvular regurgitation with new-generation devices, as compared with 8.5% incidence of paravalvular regurgitation with the early-generation devices, resulting in higher device success. Recent data from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapies (STS/ACC TVT) registry from June 2015 to November 2018 compared outcomes of 2,691 matched BAV patients with an equal number who had a tricuspid valve who were considered intermediate or high risk for open-heart surgery and underwent TAVR. There were similar rates for all-cause mortality rates at 30 days (2.6% vs. 2.4%) and one-year (10.8% vs. 12.1%) post-procedure. However, patients with a BAV had a 50% higher risk of stroke at 30 days (2.4%, vs. 1.6% for tricuspid patients). Among patients with a BAV, 0.9% encountered problems during the TAVR procedure that required converting to open-heart surgery, compared with 0.4% of patients in the tricuspid group.\[[@ref18]\]

In terms of respiratory complications, our analysis showed a significantly fewer respiratory-related complications (including post-operative pneumothorax, pulmonary edema, pulmonary collapse, prolonged mechanical ventilation, and tracheostomy) in the TAVR group. This favorable respiratory-related outcomes in TAVR is in line with previous reports and could be explained by the shorter intubation period during TAVR procedures compared to SAVR as well as the fact that open cardiac surgery would likely cause more pain and hence increased use of analgesics that can suppress the respiratory drive thus might result in respiratory failure, atelectasis, or aspiration pneumonia.\[[@ref19]\]

Limitation {#sec2-1}
----------

Our study has the following limitations. The analysis of the large administrative data is inherently prone to error because of potential inaccurate coding. However, the NIS database is a reliable source with broad applicability, given its large sample size. Outcome analysis was limited to in-hospital outcomes with no outcomes or complications after discharge were not recorded. Given the patients with BAV are often, younger compared with tricuspid AS, the durability of TAVR prosthesis is of interest, and this is what not captured in this database. In addition, TAVR procedures in this cohort of patients were done using old generation valves, and we were unable to delineate a change of outcome based on the prosthesis or delivery system that was used. However, we can assume that the Edwards SAPIEN Valve (Edwards Lifesciences, Irvine, CA) was dominantly used between the years 2011 and 2014 as the Medtronic CoreValve (Medtronic, Minneapolis, MN) received Food and Drug Administration approval in early 2014. Lastly, because of the small sample of matched patients' population, this study might not be powered enough to detect a statistically significant difference in the in-hospital mortality between SAVR and TAVR groups (0% vs. 5.9%; adjusted *P* = 0.119).

CONCLUSIONS {#sec1-5}
===========

This study shows a steadily increase in the adoption of TAVR for BAV stenosis patients in the United States along with a significant decrease in LOS. TAVR seems a safe and effective therapy in patients with BAV stenosis without aortopathy as compared with SAVR. Further research with multi-institutional studies is warranted to assess the long-term durability and complications associated with TAVR in this patient population.
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